|Slideshows|November 9, 2020

Evidence-Based Treatments for PTSD

What treatments are there to assist in the rehabilitation of veterans?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

When Brain Injury and Mental Health Look the Same: The Diagnostic Challenge of Concussion Recovery

ByBrandee Grate-Perry, MSW, LCSWA,Mena Mirhom, MD, FAPA

July 27th 2026

New Positive Data From Largest Real-World Study of Deep TMS in Patients With Comorbid PTSD and MDD

ByLeah Kuntz

June 29th 2026

FDA Grants De Novo Approval to Modius Spero, Neuromodulation Device for PTSD

ByLeah Kuntz

May 26th 2026

Childbirth-Related PTSD: Recognizing and Assessing This Unique Subtype

ByAmanda Koire, MD, PhD

May 18th 2026

FDA Fast-Tracks Psychedelic Therapies for Depression, PTSD, and Alcohol Use Disorder

ByHeidi Anne Duerr, MPH

April 24th 2026

Latest CME

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Evidence-Based Treatments for PTSD

Related Content

When Brain Injury and Mental Health Look the Same: The Diagnostic Challenge of Concussion Recovery

New Positive Data From Largest Real-World Study of Deep TMS in Patients With Comorbid PTSD and MDD

FDA Grants De Novo Approval to Modius Spero, Neuromodulation Device for PTSD

Childbirth-Related PTSD: Recognizing and Assessing This Unique Subtype

FDA Fast-Tracks Psychedelic Therapies for Depression, PTSD, and Alcohol Use Disorder

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Can Psychiatry Lead in Building Brain Capital? Why Mental Health Matters for Policy, Economy, and Society

Categories vs Dimensions: Wave or Particle?

Positive Safety and Biomarker Phase 1b Results for PMN310 Mild Cognitive Impairment and Alzheimer Disease

Attachment-Based Therapy in Adolescent Substance Users: A Meta-Synthesis of Emotional Isolation and Avoidant Attachment Patterns

FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults